Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Global Gene Therapy Market to Surge to USD 36.55 Billion by 2032 | MarketsandMarkets™

globenewswire.com
BIIB Mentioned as a leader in the consolidated gene therapy market, indicating its significant presence and potential involvement in market growth. ALNY Identified as a leading company in the gene therapy market, suggesting its active participation and potential benefit from market expansion. SRPT Listed as a key player in the gene therapy market, implying its role in the sector's growth and development. JAZZ Included as a leader in the gene therapy market, indicating its established position and potential to capitalize on market trends. PFE Mentioned as a participant in the gene therapy market, suggesting its involvement and potential to benefit from the sector's growth. JNJ BMRN Included as a participant in the gene therapy market, suggesting its role and potential to benefit from the sector's growth. QURE Mentioned as a company in the gene therapy space, indicating its involvement and potential to benefit from market growth. AMGN Listed as a company involved in the gene therapy market, suggesting its presence and potential to capitalize on market trends.

Delray Beach, FL, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Rapid innovation, expanding clinical pipelines, and rising demand for curative treatments position gene therapy as a transformative growth engine across healthcare markets

The global gene therapy market, valued at US$7.21 billion in 2023, stood at US$8.85 billion in 2024 and is projected to advance at a resilient CAGR of 19.4% from 2025 to 2032, culminating in a forecasted valuation of US$36.55 billion by the end of the period. This advancement underscores the increasing demand for curative and precision-based therapies addressing genetic disorders, rare diseases, and specific cancer types, alongside a strong surge in clinical research investments and technology breakthroughs.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=122857962

A Transformational Market Driven by Demand for Curative Solutions

What is driving this growth? The industry is witnessing unprecedented momentum as biotechnology companies, pharmaceutical leaders, and research institutions race to deliver long-term disease modification and one-time treatment cures. Approximately 19 new gene therapy products are expected to launch between 2026 and 2032, contributing nearly 25% of the total projected market value by 2032.

The rise of next-generation technologies—including CRISPR-based genome editing tools and novel vector delivery platforms—continues to reshape the therapeutic landscape. In November 2024, iotaSciences, a pioneering single-cell biology firm, introduced a rapid single-cell cloning platform specifically engineered for gene therapy, exemplifying innovation accelerating clinical deployment.

Market Barriers: High Cost and Regulatory Complexity

Despite accelerated progress, what challenges could slow market penetration? Gene therapy remains among the most expensive therapeutic categories due to the complexity of manufacturing, small patient cohorts, and stringent regulatory pathways. Research suggests that developing a single gene therapy can cost up to USD 5 billion—significantly higher than conventional pharmaceuticals.

Recent product pricing reflects the challenge:

These pricing structures constrain accessibility, particularly in lower-income regions, reinforcing cost and reimbursement models as central barriers to global market scaling.

Strategic Momentum Through Precision Medicine

Why does gene therapy matter now for global healthcare leaders? The rise of precision medicine—tailoring interventions to genetic and lifestyle profiles—is creating significant opportunity. Between 1998 and January 2024, the FDA approved 217 cancer drugs, including 181 targeted therapies and 94 precision oncology treatments, signaling strong regulatory support and clinical adoption.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=122857962

Manufacturing Challenges and Innovation Opportunities

How will the industry scale? Manufacturing remains a critical bottleneck. Viral vector production faces issues with cost, yield, storage, and regulatory compliance. Emerging technologies such as AI-optimized bioprocessing, continuous manufacturing systems, and single-use bioreactors are expected to define the next growth phase.

Global Market Landscape and Segment Outlook

Competitive Environment

The global gene therapy market remains highly consolidated, led by:

Biogen Inc. (US), Novartis AG (Switzerland), Alnylam Pharmaceuticals (US), Sarepta Therapeutics (US), Jazz Pharmaceuticals (Ireland), and others including Pfizer Inc., Johnson & Johnson, Daiichi Sankyo, BioMarin, UniQure, and Amgen.

Recent Strategic Developments Strengthening Market Momentum

Why This Matters for Business Leaders

Gene therapy is poised to transform care delivery models, reshape cost-benefit economics, and redefine competitive positioning across pharma and healthcare. Executives should expect:

For more information, Inquire Now!

Discover Connected Healthcare Market Opportunities:

Cell Therapy Technologies Market

CRISPR Market

CAR T-cell Therapy Market

Gene Transfer Technologies Market

Regenerative Medicine Market

Get access to the latest updates on Top Companies in Gene Therapy and Gene Therapy Market Size